Cell Signaling Technology

Mena (D33C1) Rabbit Monoclonal Antibody

#6921 · $161,351

65
Evidence Score · Well-Established
Used by 191 independent labs across 202 papers. How we score this →
100
Citing papers
7.3k
Combined citations
Supplier page Find this product

Research areas

Cancer, Hypoxia, and Metabolism25PI3K/AKT/mTOR signaling in cancer11Lung Cancer Treatments and Mutations8Cancer-related Molecular Pathways6Metabolism, Diabetes, and Cancer6RNA modifications and cancer5Glycosylation and Glycoproteins Research5Cancer Cells and Metastasis4

Papers citing this product

1
Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor <i>BRAF</i> gene mutations but lack mutations in <i>KRAS, NRAS,</i> or <i>MEK1</i>
Proceedings of the National Academy of Sciences·2012·436 cit.·DOI
2
Lactate promotes endothelial-to-mesenchymal transition via Snail1 lactylation after myocardial infarction
Science Advances·2023·352 cit.·DOI
3
Targeting the facilitative glucose transporter GLUT1 inhibits the self-renewal and tumor-initiating capacity of cancer stem cells
Oncotarget·2014·196 cit.·DOI
4
ZBP1/DAI ubiquitination and sensing of influenza vRNPs activate programmed cell death
The Journal of Experimental Medicine·2017·190 cit.·DOI
5
Osteoclast Response to Low Extracellular Sodium and the Mechanism of Hyponatremia-induced Bone Loss
Journal of Biological Chemistry·2010·188 cit.·DOI
6
Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer
Nature Communications·2017·182 cit.·DOI
7
Caspase-dependent and -independent Activation of Acid Sphingomyelinase Signaling
Journal of Biological Chemistry·2005·162 cit.·DOI
8
PIK3CA Mutations Frequently Coexist with EGFR/KRAS Mutations in Non-Small Cell Lung Cancer and Suggest Poor Prognosis in EGFR/KRAS Wildtype Subgroup
PLoS ONE·2014·162 cit.·DOI
9
The distinct metabolic phenotype of lung squamous cell carcinoma defines selective vulnerability to glycolytic inhibition
Nature Communications·2017·149 cit.·DOI
10
Remodeling tumor immune microenvironment (TIME) for glioma therapy using multi-targeting liposomal codelivery
Journal for ImmunoTherapy of Cancer·2020·134 cit.·DOI

Similar products

ProductVendorEvidencePricePapers
Mena AntibodyRabbitCell Signaling Technology65$317100
Mena (E8H6R) Rabbit Monoclonal AntibodyRabbitCell Signaling Technology65$161,3511
Mena (F5Z9K) Rabbit Monoclonal AntibodyRabbitCell Signaling Technology65$178,4151

Rate this reagent

Used this in your lab? Leave a quick rating. Reviews are anonymous and verified by academic email before they appear.

Your email is never shown publicly.